Skip to content
News
Archive
News and Press Releases
Title
Date
Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies
August 31, 2023
Syncromune, Inc. Enters Into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., LTD., to Develop and Commercialize YH002 (OX40 Anibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax Combination Immunotherapy Platform
October 18, 2022
Syncromune, Inc. to Present at 2022 BIO CEO & Investor Conference
February 12, 2022
